Stockscreener 앱 받기
3.30
6.77%
-0.2395
전일 마감가:
$3.5395
열려 있는:
$3.41
하루 거래량:
194.76K
Relative Volume:
0.54
시가총액:
$4.41M
수익:
-
순이익/손실:
$-13.52M
주가수익비율:
-4.4595
EPS:
-0.74
순현금흐름:
$-10.03M
1주 성능:
-9.60%
1개월 성능:
-34.00%
6개월 성능:
-87.47%
1년 성능:
-80.83%
1일 변동 폭
$2.86
$4.16
1주일 범위
$2.86
$4.16
52주 변동 폭
$2.86
$79.00
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
명칭
Kazia Therapeutics Limited Adr
전화
01161298780088
주소
140 WICKS RD, NEW SOUTH WALES 2113, NSW
KZIA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
3.30 | 4.41M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | Maxim Group | Buy |
| 2021-10-14 | 개시 | Maxim Group | Buy |
| 2021-01-05 | 개시 | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr 주식(KZIA)의 최신 뉴스
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
Kazia Therapeutics sells Cantrixil rights for $1 million - Investing.com India
Kazia's Million-Dollar Deal: Cantrixil Cancer Drug IP Rights Sold as Development Path Shifts - Stock Titan
Kazia Therapeutics shares annual report details By Investing.com - Investing.com South Africa
Kazia Therapeutics shares annual report details - Investing.com
Best upcoming stock splits and reverse splits 2024 - Investorsobserver
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease - BioSpace
Kazia explores paxalisib for Parkinson's with MJFF grant - Investing.com
Can This Brain-Penetrating Drug Breakthrough Transform Parkinson's Treatment? Major Foundation Thinks So - Stock Titan
KZIA’s Stock Journey: What Investors Need to Know About Kazia Therapeutics Limited ADR’s Performance - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) Stock: Analyzing the Market Value - The News Heater
SolarBank Corporation (SUUN) Stock: Evaluating the Market Performance - The News Heater
Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater
Maxim Group Begins Coverage on Kazia Therapeutics (NASDAQ:KZIA) - Defense World
10 Best ASX Stocks to Buy According to Hedge Funds - Insider Monkey
Game-Changing Cancer Trial: Kazia's New Drug Combo Could Unmask Hidden Breast Cancer Cells - StockTitan
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? - Insider Monkey
10 Best Australian Stocks to Buy Now - Insider Monkey
Kazia Therapeutics Secures $2M Funding Through Direct Offering to Alumni Capital - StockTitan
Kazia Therapeutics secures $2 million in direct offering - Investing.com India
Kazia Therapeutics Secures $2M Funding Through Direct Offering at $1.50 Per ADS - StockTitan
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Yahoo Finance
Kazia aligns with FDA on glioblastoma drug study design - Investing.com India
Kazia's Brain Cancer Drug Paxalisib Shows 3.8-Month Survival Benefit, FDA Guides Phase 3 Path Forward - StockTitan
Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan
Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance
B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga
Paxalisib shows promise in brain metastasis treatment - Investing.com
Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan
Kazia Therapeutics Limited ADR (KZIA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immunotherapy Clinical TrialsA New Approach to Treating Cancer - StockTitan
Take off with Kazia Therapeutics Limited ADR (KZIA): Get ready for trading - SETE News
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER - MarketScreener
7 Top Stocks Under $10: July 2024 Edition - InvestorPlace
United States shares higher at close of trade; Dow Jones Industrial Average up 0.53% - Investing.com India
United States shares higher at close of trade; Dow Jones Industrial Average up 0.62% - Investing.com India
Kazia Therapeutics Limited Adr (KZIA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):